Clinical trials: Oral Anticoagulant
Anticoagulant Drugs, Diabetes Mellitus, Type 2
Effect of an Electronic Reminder System on Direct Oral Anticoagulant and Oral Diabetes Medication Adherence
In this study, the effect of an electronic device attached to a push through pill package and a smart phone application on chronic disease medication adherence is studied.
- Trial name
- NCT03753568
- Testing
- Electronic medicine reminder system
- Where
- Finland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Acute Myocardial Infarction
Efficacy and Safety of Direct Oral Anticoagulants for the Treatment of Mural Thrombus
To describe the prescribing patterns at Methodist Dallas Medical Center (MDMC) for the treatment of newly diagnosed mural thrombus and to determine the efficacy and safety of DOACs apixaban, dabigatran, and rivaroxaban in…
- Trial name
- NCT04153591
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Methodist Health System
Anticoagulant-induced Bleeding, Direct Oral Anticoagulant
Peri-procedural Management of Direct Oral Anticoagulants for Central VENOus Catheters in CAncer Patients With Venous Thromboembolism or Atrial Fibrillation Pilot Study
The peri-procedural management of direct oral anticoagulants (DOACs) in persons with cancer (PWC) undergoing tunneled or port central venous catheter (CVC) insertion is a common but understudied clinical problem, with conflicting…
- Conditions
- Anticoagulant-induced Bleeding, Direct Oral Anticoagulant, Cancer, Central Venous Catheter
- Trial name
- VENO CAT (NCT06887270)
- Testing
- Continued DOAC, Interrupted DOAC
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Anticoagulants and Bleeding Disorders
Bleeding Oral Anticoagulant Analyzer (BOA)
The quality of the reversion of these serious hemorrhagic accidents under oral anticoagulants depends on the adequate use of reversion products but also on the speed of obtaining hemostasis data allowing to evaluate the…
- Trial name
- BOA (NCT05026281)
- Testing
- Quantra analyzer
- Where
- 6 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Clermont-Ferrand
Anticoagulants and Bleeding Disorders, Surgery
Oral Surgery in Patients Taking Direct Oral Anticoagulants
This study evaluates the incidence of postoperative bleeding after oral surgical procedures in patients taking direct oral anticoagulants and in patients taking vitamin K antagonists.
- Conditions
- Anticoagulants and Bleeding Disorders, Surgery, Postoperative Hemorrhage, Dentoalveolar Haemorrhage
- Trial name
- OSDOA (NCT04505475)
- Testing
- Oral surgical procedure followed by local hemostatic measures (insertion of gelatine sponge and wound suturing)
- Where
- Serbia
- Volunteers
- 82 people
- Sponsor
- University of Novi Sad
Benign Prostatic Hyperplasia, Anticoagulant Adverse Reaction
Stop or Ongoing Oral Anticoagulation in Patients Undergoing Pvp (SOAP)
Benign prostatic hyperplasia (BPH) is a very common pathology of the aging man with an incidence that rises from 40% in men aged 50 to 60 years to 90% in men over 80 years.
- Trial name
- SOAP (NCT03297281)
- Testing
- Maintenance of OAC in surgery of BPH by PVP., Discontinuation of OAC in surgery of BPH by PVP.
- Where
- France
- Volunteers
- 389 people
- Sponsor
- Clinique Pasteur
Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee
Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin
This clinical study aims to evaluate the efficacy and safety of the anticoagulant Dimolegin® compared to low molecular weight heparin (Clexane®) for the prevention of venous thromboembolic events (VTE) in patients undergoing…
- Conditions
- Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Venous Thromboembolism (VTE), Prevention
- Trial name
- NCT07124819
- Testing
- Sodium enoxaparin, Dimolegin
- Where
- 8 sites in Russia
- Volunteers
- 215 people
- Sponsor
- Avexima Diol LLC
Atrial Fibrillation
Study of DU-176b Aged 80 Years or Older
The purpose of this study is to evaluate the efficacy and safety of edoxaban in patients with non-valvular NVAF aged 80 years or older who are ineligible for available oral anticoagulation therapy.
- Trial name
- NCT02801669
- Testing
- Du-176b
- Where
- 164 sites in Japan
- Volunteers
- 984 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Atrial Fibrillation
MultiCenter expeRience in AFib Patients Treated With OAC (CRAFT)
According to current guidelines for non-valvular atrial fibrillation treatment, the first line drugs are non-vitamin K oral anticoagulants (NOACs), which are preferred over vitamin K antagonists (VKAs).
- Trial name
- CRAFT (NCT02987062)
- Where
- 2 sites in Poland
- Volunteers
- 2,000 people
- Sponsor
- Medical University of Warsaw
Non-Valvular Atrial Fibrillation (NVAF)
A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan
The purpose of this observational study is to understand real-world oral anticoagulants (OAC) (warfarin, apixaban, dabigatran, edoxaban and rivaroxaban) usage for non-valvular atrial fibrillation (NVAF) patients.
- Trial name
- NCT05027061
- Where
- Japan
- Volunteers
- 11,776 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Pill-in-the-POCKET Oral Anticoagulation Strategy After AF Catheter Ablation
The clinical benefit of pill-in-the-POCKET anticoagulation after atrial fibrillation catheter ablation remains uncertain. We aimed to evaluate the clinical benefit and safety of pill-in-the-POCKET anticoagulation after atrial…
- Trial name
- POCKET-OAC (NCT06216769)
- Testing
- Rivaroxaban
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Seoul National University Hospital
Atrial Fibrillation
A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage
The primary purpose of this study is to evaluate the risk of major bleeding and stroke/systemic embolism (SE) among novel oral anti-coagulant (OAC) naïve and warfarin naïve Medicare Advantage patients with non-valvular atrial…
- Trial name
- NCT03189069
- Testing
- Apixaban, Dabigatran, Rivaroxaban
- Volunteers
- 36,000 people
- Sponsor
- Bristol-Myers Squibb
Deep Vein Thrombosis
The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis
Isolated distal DVT (iDDVT) is the most frequent clinical presentation of VTE and is associated with a significant morbidity and risks of long-term complications.
- Trial name
- API-CALF (NCT04981327)
- Testing
- Apixaban 2.5 MG Oral Tablet [ELIQUIS]
- Volunteers
- 1,300 people
- Sponsor
- University Hospital, Geneva
Atrial Fibrillation
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
A prospective non-interventional single-centre study aimed to evaluate actual adherence of AF patients using the validated adherence Scale.
- Trial name
- ANTEY (NCT03790917)
- Where
- Russia
- Volunteers
- 201 people
- Sponsor
- National Research Center for Preventive Medicine
Healthy
PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers
This study aims to evaluate the effects of combination therapy of tegoprazan and novel oral anticoagulants (NOACs) on the pharmacokinetic and pharmacodynamic properties of NOACs in healthy adults.
- Trial name
- NCT05723510
- Testing
- Tegoprazan 50mg, Edoxaban 60mg, Apixaban 5mg
- Where
- South Korea
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Atrial Fibrillation
COhort of antithrOmbotic Use and cLinical Outcomes in Patients With Atrial Fibrillation (COOL-AF) Phase 2
Atrial fibrillation (AF) is a leading cause of cardiovascular mortality and morbidity. Asian patients with AF have a higher rate of major bleeding including intracranial hemorrhage (ICH) compared to non-Asians.
- Trial name
- NCT06396299
- Testing
- No intervention
- Where
- 33 sites in Thailand
- Volunteers
- 4,000 people
- Sponsor
- Mahidol University
Intracerebral Hemorrhage, Intracerebral Haemorrhage
International Care Bundle Evaluation in Cerebral Hemorrhage Research
Spontaneous intracerebral haemorrhage (ICH) accounts for approximately 10-15% of all strokes but stands for 50% of stroke-related morbidity and mortality.
- Conditions
- Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke
- Trial name
- I-CATCHER (NCT06429332)
- Testing
- Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia
- Where
- 54 sites in United States, Australia and 6 more
- Volunteers
- 3,500 people
- Sponsor
- Region Skane
Anticoagulants, Drug Interactions
Shared Decision for Drug Interactions in Oral Anticoagulation
The purpose of this project is to implement and evaluate a shared-decision making (SDM) tool called DDInteract that was developed to support decision making for drug-drugs interactions while on oral anticoagulants.
- Trial name
- DDInteract (NCT06401863)
- Testing
- Shared Decision Making Tool
- Where
- 3 sites in United States
- Volunteers
- 610 people
- Sponsor
- University of Utah
Hemorrhage, Thrombosis
Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department
Rationale: According to the latest National Survey on Care-Related Adverse Events, anticoagulants, including vitamin K antagonists (VKAs), rank first among medications responsible for serious iatrogenic accidents (37% in 2004…
- Conditions
- Hemorrhage, Thrombosis, Anticoagulant Therapy, Traumatic Hemorrhage
- Trial name
- ADEOA (NCT06692504)
- Where
- France
- Volunteers
- 2,080 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Venous Thrombosis, Cardiovascular Diseases
Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
To perform a randomized clinical trial comparing continuing one month of treatment with heparin in patients with deep venous thrombosis to standard care using heparin for five days and oral warfarin for three months.
- Conditions
- Venous Thrombosis, Cardiovascular Diseases, Venous Thromboembolism
- Trial name
- NCT00005684
- Testing
- warfarin, heparin
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)